"We are pleased to announce the important milestone of enrollment completion in this study aimed at treating this unmet medical need," Christopher J. Schaber, president and CEO of Soligenix, said. "We appreciate the efforts of the clinicians involved with the study as well as the participation from the patients. We are looking forward with great anticipation to announcing the results of this study later this year."
SGX942, a first-in-class innate defense regulator, is being evaluated as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
This Phase 2 study is a randomized, double blind, dose-ranging, placebo-controlled trial, set to enroll approximately 75 subjects across 3 SGX942 dose groups and a placebo group. The trial is focused on demonstrating the safety and biologic activity of SGX942 in patients with cancer of the mouth and oropharynx who often experience debilitating oral mucositis as a consequence of chemoradiation therapy.
Soligenix develops products that address unmet medical needs in the areas of inflammation, oncology and biodefense.